Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.30 |
| ▸ | MME | P08473 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1204546 | 0.98 | TDP1 (0.40) | TDP1SMN1; SMN2SLC22A6GRIK1GRIK2 | |
| SCHEMBL1204544 | 0.98 | TDP1 (0.40) | TDP1SMN1; SMN2SLC22A6GRIK1GRIK2 | |
| SCHEMBL28904430 | 0.95 | TDP1 (0.39) | TDP1SMN1; SMN2SLC22A6GRIK1GRIK2 | |
| SCHEMBL27637478 | 0.82 | SLC22A6 (0.35) | TDP1SMN1; SMN2SLC22A6MAPTHDAC2 | |
| Hydrochloric Acid SCHEMBL4148164 | 0.81 | GABRR1 (0.34) | GRIK1GRIK2GABRR1 | |
| SCHEMBL5076843 | 0.76 | — | — | |
| SCHEMBL10928741 | 0.76 | — | — | |
| SCHEMBL5076842 | 0.76 | — | — | |
| SCHEMBL15447441 | 0.76 | — | — | |
| SCHEMBL40726 | 0.76 | TDP1 (0.37) | TDP1SMN1; SMN2SLC22A6GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9517203-B2 | Polymer particle delivery compositions and methods of use | MEDIV AS, LLC (US) | 2016-12-13 | — | — | US | disclosed |
| EP-2413909-B1 | MULTIAMINO ACID-BASED POLY (ESTER AMIDE)S | UNIV CORNELL (US) | 2016-11-30 | — | — | EP | disclosed |
| US-9102830-B2 | Bis-(α-amino)-diol-diester-containing poly (ester amide) and poly (ester urethane) compositions and methods of use | MEDIVAS, LLC (US) | 2015-08-11 | — | — | US | disclosed |
| US-8993686-B2 | Multiamino acid-based poly(ester amide)s | CORNELL UNIVERSITY (US) | 2015-03-31 | — | — | US | disclosed |
| US-8652504-B2 | Solid polymer delivery compositions and methods for use thereof | MEDIVAS, LLC (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130210931-A1 | BIS-(ALPHA-AMINO)-DIOL-DIESTER-CONTAINING POLY (ESTER AMIDE) AND POLY (ESTER URETHANE) COMPOSITIONS AND METHODS OF USE | MEDIVAS, LLC (US) | 2013-08-15 | — | — | US | disclosed |
| EP-1926780-B1 | BIS-( -AMINO)-DIOL-DIESTER-CONTAINING POLY(ESTER AMIDE) AND POLY(ESTER URETHANE) COMPOSITIONS AND METHODS OF USE | MEDIVAS LLC (US) | 2013-08-14 | — | — | EP | disclosed |
| US-8445007-B2 | Bis-(α-amino)-diol-diester-containing poly (ester amide) and poly (ester urethane) compositions and methods of use | MEDIVAS, LLC (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445627-B2 | Alkylene-dicarboxylate-containing biodegradable poly(ester-amides) and methods of use | MEDIVAS, LLC (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120328706-A1 | POLYMER PARTICLE DELIVERY COMPOSITIONS AND METHODS OF USE | MEDIVAS, LLC (US) | 2012-12-27 | — | — | US | disclosed |
| US-20060188486-A1 | Wound care polymer compositions and methods for use thereof | MEDIVAS, LLC (US) | 2006-08-24 | — | — | US | disclosed |
| US-20060177416-A1 | Polymer particle delivery compositions and methods of use | MEDIVAS, LLC (US) | 2006-08-10 | — | — | US | disclosed |
| WO-2006083874-A2 | VACCINE DELIVERY COMPOSITIONS AND METHODS OF USE | MEDIVAS, LLC. (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006050091-A2 | BIOACTIVE WOUND DRESSINGS AND IMPLANTABLE DEVICES AND METHODS OF USE | MEDIVAS, LLC (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20060024357-A1 | Wound healing polymer compositions and methods for use thereof | MEDIVAS, LLC (US) | 2006-02-02 | — | — | US | disclosed |
| US-20060013855-A1 | Bioactive stents for type II diabetics and methods for use thereof | MEDIVAS, LLC (US) | 2006-01-19 | — | — | US | disclosed |
| WO-2005121250-A2 | UNSATURATED POLY(ESTER-AMIDE) BIOMATERIALS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005112587-A2 | WOUND HEALING POLYMER COMPOSITIONS AND METHODS FOR USE THEREOF | MEDIVAS, LLC (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050238689-A1 | Bioactive stents for type II diabetics and methods for use thereof | MEDIVAS, LLC (US) | 2005-10-27 | — | — | US | disclosed |
| WO-2005097186-A2 | BIOACTIVE STENTS FOR TYPE II DIABETICS AND METHODS FOR USE THEREOF | MEDIVAS, LLC (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050238689-A1 | Bioactive stents for type II diabetics and methods for use thereof | CD47, ITGB2, ITGA2 | HDAC2 2116/4885TDP1 4248/4885SMN1; SMN2 2459/4885 |
| US-20060024357-A1 | Wound healing polymer compositions and methods for use thereof | BMP2, GLO1, LANCL2 | HDAC2 1028/4885TDP1 2884/4885SMN1; SMN2 2910/4885 |
| US-20120328706-A1 | POLYMER PARTICLE DELIVERY COMPOSITIONS AND METHODS OF USE | GRPR, PLAUR, PCNP | HDAC2 2494/4885TDP1 372/4885SMN1; SMN2 1743/4885 |
| US-20060177416-A1 | Polymer particle delivery compositions and methods of use | GRPR, PLAUR, PCNP | HDAC2 2494/4885TDP1 372/4885SMN1; SMN2 1743/4885 |
| US-20060188486-A1 | Wound care polymer compositions and methods for use thereof | CUTA, NACA, FAM83A | HDAC2 2325/4885TDP1 3013/4885SMN1; SMN2 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.